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S U M M A R Y
Objective: To evaluate the efﬁcacy and safety of adjunctive therapy using interferon-gamma (IFN-g; an
immunomodulator) for the treatment of pulmonary tuberculosis (TB).
Methods: We conducted a systematic review of controlled clinical trials that compared anti-TB drugs in
combination with IFN-g with the same anti-TB drugs alone for the treatment of pulmonary TB.
Results: Nine trials were identiﬁed, with IFN-g being aerosolized or administered subcutaneously in one
trial, aerosolized only in ﬁve trials, and administered intramuscularly in three trials. The methodology
quality of all trials was rated ‘C’. Meta-analysis of the trials with aerosolized IFN-g showed statistical
beneﬁts on sputum negative conversion and chest radiograph: the pooled relative risk (RR) for
conversion was 1.97 (95% conﬁdence interval (CI) 1.20–3.24, p = 0.008) after 1 month of treatment, 1.74
(95% CI 1.30–2.34, p = 0.0002) after 2 months of treatment, 1.53 (95% CI 1.16–2.01, p = 0.003) after 3
months of treatment, 1.57 (95% CI 1.20–2.06, p = 0.001) after 6 months of treatment, and 1.55 (95% CI
1.17–2.05, p = 0.002) at the end of treatment; the pooled RR for the chest radiograph was 1.38 (95% CI
1.10–1.17, p = 0.006) at the end of treatment. For intramuscularly administered IFN-g, meta-analysis of
three trials showed its signiﬁcant improvement on sputum negative conversion after 2 months of
treatment. A randomized controlled trial with aerosolized and subcutaneously administered IFN-g
reported signiﬁcant reductions in the symptoms of fever, wheeze, and night sweats in the IFN-g-treated
groups compared with the control group after 1 month of treatment. No patients discontinued treatment
because of adverse effects caused by IFN-g.
Conclusion: Adjuvant therapy using IFN-g, especially by aerosol, might be beneﬁcial to TB patients, but
large randomized controlled trials are needed for further evaluation of its efﬁcacy and safety considering
the quality of the trials analyzed.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Tuberculosis (TB) is a major cause of illness and death, and the
worldwide epidemic of HIV/AIDS and emergence of multidrug-
resistant TB (MDR-TB), or even extensively drug-resistant TB
(XDR-TB), are exacerbating this global problem.1,2 Recent global
estimates showed 9.27 million new cases of TB and 1.77 million
deaths from TB in 2007.3
The incidence and progression of TB is closely related to the host
immune condition. The immune response to the tubercle bacilli
mainly takes the classic form of delayed-type hypersensitivity,
which is thought to be mediated by a cooperative interaction
between T-lymphocytes and macrophages, depending upon the* Corresponding author. Tel.: +86 0817 2242774.
E-mail address: xfgao_nsmc@163.com (X.-F. Gao).
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doi:10.1016/j.ijid.2011.05.002interplay of cytokines produced by a variety of mononuclear cells.4
The progression of TB may be associated with cellular immunode-
ﬁciency.5 Conventional anti-tubercular chemotherapy combined
with immunotherapeutic modalities could therefore be a promis-
ing new approach for the treatment of TB. As indicated in a meta-
analysis, the use of Mycobacterium vaccae as an immunomodulator
is helpful for patients with recurrent pulmonary TB (PTB).6
Interferon-gamma (IFN-g), made by immune cells, is a highly
pleiotropic cytokine with immunomodulatory antimicrobial,
antiproliferative, and antiﬁbrotic activities that also modulates
the production or activities of several cytokines and chemokines.7–
9 Early animal models and pharmacokinetic and pharmacodynam-
ic studies suggested that adjunctive therapy with IFN-g may favor
recovery from PTB.10–12 Some uncontrolled studies in humans also
showed that the adjunctive therapy could improve TB progression
and was well tolerated by MDR-TB patients.13,14 However, there
were uncontrolled studies showing that the adjunctive therapy didses. Published by Elsevier Ltd. All rights reserved.
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Figure 1. Results of the search for controlled clinical trials (CCTs) in the systematic
review.
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advanced MDR-TB.15,16 Hence, adjunctive immunotherapy with
IFN-g needs to be evaluated in controlled trials. Some controlled
clinical trials with adjunctive IFN-g have recently been completed,
and we therefore conducted a systematic review of the trials on the
efﬁcacy and safety of adjunctive IFN-g therapy for TB, in order to
provide timely evidence-based information for TB physicians.
2. Methods
2.1. Selection criteria
We included controlled clinical trials that met the following
criteria: (1) Participants. Eligible participants were patients with
drug-susceptible or drug-resistant PTB conﬁrmed by sputum
smear and/or culture. (2) Intervention. Only trials that directly
compared IFN-g plus anti-TB drugs with the same anti-TB drugs
alone were included. (3) Outcome measures. The primary outcome
was sputum negative conversion (sputum smear and/or Mycobac-
terium tuberculosis culture) at a speciﬁc number of months after
therapy. The secondary outcomes included chest radiographic
improvement and (severe) adverse events. Chest radiographic
improvement was deﬁned as a decrease in the extent of lesions in
the lungs, or a >50% decrease in the cavity size at a speciﬁc number
of months after treatment. Severe adverse events, including severe
hepatotoxicity, were deﬁned as serious adverse drug reactions that
ﬁnally led to hospitalization of the patient or discontinuation of
treatment, and were determined by the authors based on
symptoms, physical signs, and/or laboratory examination.17,18
Other outcomes included biochemical variables (e.g., serum
interleukin (IL)-4, IFN-g) reﬂecting immune function, and bacteri-
ological relapse after completion of treatment. (4) Language of
articles. We limited languages to English and Chinese in this study.
2.2. Search strategy and study selection
We searched published information in Medline (1966 to April
2010), the Cochrane Central Register of Controlled Trials (CEN-
TRAL, Cochrane Library issue 1, 2010), the Chinese Biomedical
Literature Database (CBM, 1978 to April 2010), and the VIP
Database (1989 to May 2010), and unpublished information in the
WANFANG Database (up to May 2010) and at ‘ClinicalTrials.gov’.
CBM, VIP, and WANFANG are widely used databases in China,
which extensively index articles published in journals and
conference proceedings in Chinese. We searched these databases
using the search strategy of ‘(tuberculosis OR TB) AND (interferon
OR IFN)’. We also scanned the reference lists of all relevant articlesTable 1
Methodology quality of the trials included in this review
Trial Randomizationa Allocation
concealmentb
Blinding
Dawson et al., 200919 A B C 
Yang et al., 200921 A C C 
Zhang et al., 200922 Cg C C 
Shi et al., 200823 C C C 
Li et al., 200824 C C C 
Wang et al., 200625 C C C 
Xu, 200626 C C C 
Liang, 200327 C C C 
Yao and Liu, 200328 Cg C C 
a A = adequate, B = unclear (randomization was reported, but the method not describ
b A = adequate, B = unclear (not mentioned), C = clearly inadequate concealment/not u
c A = adequate, B = unclear (not mentioned), C = not used (‘open-label’ or ‘unmasked’ 
d A = adequate reporting (including numbers and causes), B = partly reported, C = not
e A = comparable (at least including age and sex), B = unclear, C = not comparable.
f A = low risk of bias, B = moderate risk of bias, C = high risk of bias.
g Temporarily regarded as non-randomized trials due to our failure to contact the afor the selection of controlled clinical trials. Figure 1 shows the
process by which articles were selected.
2.3. Review procedure
Two reviewers independently selected the trials for inclusion,
assessed the quality of the trials, and extracted data in the form of a
predeﬁned table. Discrepancies were resolved through discussion
or by the third party. We contacted the authors of the trials for
missing information by telephone. For trials published in Chinese
journals, we inquired, using pre-designed questions, about their
method of allocating participants, to judge whether the trial was
randomized or not. As the trial by Dawson et al.19 compared
chemotherapy combined with aerosolized or subcutaneously
administered IFN-g with chemotherapy alone, we separately
analyzed the comparison between chemotherapy combined with
aerosolized IFN-g and chemotherapy alone, and the comparison
between chemotherapy combined with subcutaneously adminis-
tered IFN-g and chemotherapy alone.
The methodology quality of each trial was evaluated according
to the following ﬁve predeﬁned items: randomization, allocation
concealment, blinding, reporting loss to follow-up or withdrawal,
and comparability of baseline. Each item was rated as A, B, or C
(Table 1) in accordance with the Cochrane handbook.20 When all
ﬁve items were rated A, the trial was considered high quality
(overall grade A); when one or more items were rated C, the trialc Reporting loss
of follow-up/withdrawald
Comparability
of baselinee
Overall gradef
A A C
A A C
C B C
C A C
A A C
B A C
C A C
A A C
C A C
ed), C = inadequate (quasi-randomization or non-randomization).
sed.
trials).
 reported.
uthors.
Table 2
Anti-tuberculosis drug regimens and interferon-g therapy of the trials in this review
Trial, year (country),
reference
Trial participants Anti-TB drug regimens
in control and treatment
groupsa
IFN-g immunotherapy in the treatment group Follow-up time
(months)
Dawson et al., 2009
(South Africa)19
Drug-sensitive, cavitary,
culture-positive PTB
2HRZE/4HR Human recombinant IFN-g1b: 2 MU/dose,
aerosol or subcutaneous injection, three times
weekly for 4 months
12
Yang et al., 2009 (China)21 Multidrug-resistant PTB 3SpPaZETh/9SpPaE Human recombinant IFN-g: 1 MU/dose, aerosol,
three times weekly for 2 months
12
Zhang et al., 2009 (China)22 Previously treated, smear-
or culture- positive PTB
2LPaThV/? IFN-g: 5 MU/dose, aerosol, three times weekly for
2 months
2
Shi et al., 2008 (China)23 Multidrug-resistant PTB 3HPEZAkhV/9EZV Human recombinant IFN-g: 2 MU/dose, aerosol,
three times weekly for 6 months
6
Li et al., 2008 (China)24 Previously untreated, smear-
or culture- positive PTB
2HRZE/4HR Human recombinant IFN-g: 1 MU/dose,
intramuscular injection, three times weekly for 2
months
2
Wang et al., 2006 (China)25 Previously untreated, smear-
or culture- positive PTB
2SHRZ/4HR(E)
or 2HREZ/4HR(E)
Human recombinant IFN-g: 1 MU/dose,
intramuscular injection, three times weekly for 2
months
6
Xu, 2006 (China)26 Multidrug-resistant PTB 3AkPaThVL/15PaThVL IFN-g: 5 MU/dose, aerosol, three times weekly for
3 months
3
Liang, 2003 (China)27 Previously treated, smear-
or culture-positive PTB
2H3R3Z3S3E3/6H3R3E3 IFN-g: 1 MU/dose, intramuscular injection, three
times weekly for 2 months
8
Yao and Liu, 2003 (China)28 Multidrug-resistant PTB 3KmPaZEO/6PaEO Human recombinant IFN-g: 1 MU/dose, aerosol,
three times weekly for 3 months
9
TB, tuberculosis; PTB, pulmonary tuberculosis; IFN-g, interferon-gamma; MU, million units.
a Numbers before the letters indicate the duration of the treatment phase in months; subscript numbers indicate the number of times the drug was taken each week; H,
isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol; S, streptomycin; P, para-aminosalicylic acid; Akh, amikacin hydrochloride; Ak, amikacin; Sp, sparﬂoxacin; V,
levoﬂoxacin; Th, prothionamide; Km, kanamycin; Pa, pasiniazide; O, oﬂoxacin; L, rifapentine; ?, without report of drugs used in the continuation phase.
X.-F. Gao et al. / International Journal of Infectious Diseases 15 (2011) e594–e600e596was considered low quality (overall grade C); and when one or
more items were rated B and no items were rated C, the trial was
considered of moderate quality (overall grade B), see Table 1.
2.4. Statistical analysis
According to the intention-to-treat principle, we performed a
meta-analysis of the trials to explore the effects of IFN-g.
Treatment effects were summarized as the relative risk (RR) for
binary variables and as the weighted mean difference (WMD) for
numerical variables. The Z-test was used for the pooled effect size,
and the statistical signiﬁcance of difference was set at p  0.05. We
also calculated the 95% conﬁdence interval (CI) of the pooled effect
size. The heterogeneity of treatment effects among trials was
detected using the Chi-square test and I2 statistics. Statistical
heterogeneity was set at p  0.1. When statistical heterogeneity
was not detected, the pooled effect was calculated using a ﬁxed
effect model; when heterogeneity was detected, we tried to ﬁnd
the sources of heterogeneity and then used a random effects model
to calculate the pooled effect when it was still appropriate to
combine trials. All analyses were performed using RevMan 4.2
software (The Cochrane Collaboration, Oxford, UK).
3. Results
3.1. Trials included
Nine trials, reported between 1998 and 2009, were identiﬁed in
this study.19,21–28 In our literature search, we temporarily excluded
one relevant trial (clinical trial identiﬁer: NCT00001407) because
of our failure to obtain the data.29 Eight of the included trials were
conducted in China21–28 and one in South Africa.19 Three trials
were conducted in patients with drug-sensitive or previously
untreated, smear- or culture-positive PTB,19,24,25 four in patients
with multidrug-resistant PTB,21,23,26,28 and two in patients with
previously treated, culture-positive PTB (Table 2).22,27 Anti-TBdrug regimens varied in the trials. The IFN-g intervention was
given three times weekly, but its administration route and dose
varied in the trials. One trial used aerosolized and subcutaneously
administered IFN-g at 2 million units (MU) per dose,19 ﬁve used
only aerosolized IFN-g at 1, 2, or 5 MU per dose,21–23,26,28 and the
other three used intramuscularly administered IFN-g at 1 MU per
dose .24,25,27 The IFN-g interventions lasted 2–4 months in eight
trials19,21,22,24–28 and 6 months in one trial.23 All trials were open-
labeled (Table 1). According to our telephone interview, two
trials19,21 were randomized, two trials23,25 were quasi-randomized
because of the alternate allocation of TB patients, three24,26,27 were
non-randomized because of the allocation of TB patients based on
patient opinion, and in two this was unclear because of our failure
to contact the authors.22,28 The latter two trials22,28 were
temporarily regarded as non-randomized trials as the trials were
conducted in class 2 (county-level) hospitals where authentic
randomized trials were rarely carried out.30
3.2. Sputum negative conversion rates
As chemotherapy combined with aerosolized or subcutaneous-
ly administered IFN-g were simultaneously compared with
chemotherapy alone in one included trial,19 we did not calculate
the total effect of the outcomes. Instead, we performed a subgroup
analysis according to the IFN-g administration route.
Of the nine trials evaluating therapy with IFN-g, two reported
sputum smear negative conversion rates after 1 month of
treatment,19,26 ﬁve after 2 months of treatment,22,24–27 three after
3 months of treatment,21,26,28 four after 6 months of treat-
ment,21,23,25,28 and four at completion of chemotherapy.21,25,27,28
One randomized controlled trial (RCT)21 with aerosolized IFN-g
reported higher smear conversion rates in the IFN-g-treated group
compared with the control group after 3 or 6 months of treatment
or at the completion of chemotherapy, although there were no
statistically signiﬁcant differences between the IFN-g-treated and
the control groups at these time-points. However, another RCT19
Table 3
Sputum smear negative conversion-related results of the trials included in this review
Administration
route
Trial design Sputum negative conversion Trial Treatment
n/N
Control n/N RR (95% CI) p-Valuea p-Valueb
Aerosol RCT After 1 month of treatment Dawson et al., 200919 20c/32 11c/30 1.70 (0.99–2.93) - 0.05
After 3 months of treatment Yang et al., 200921 18/30 13/30 1.38 (0.84–2.29) - 0.20
After 6 months of treatment Yang et al., 200921 21/30 15/30 1.40 (0.91–2.15) - 0.12
At completion of treatment Yang et al., 200921 23/30 16/30 1.44 (0.97–2.12) 0.07
Non-RCT After 1 month of treatment Xu, 200626 10/23 3/20 2.90 (0.92–9.09) - 0.07
After 2 months of treatment Zhang et al., 200922 32/35 21/35 1.52 (1.14–2.03)
Xu, 200626 15/23 5/20 2.61 (1.15–5.90)
Subtotal 47/58 26/55 1.74 (1.30–2.34) 0.18 0.0002
After 3 months of treatment Xu, 200626 19/23 10/20 1.65 (1.03–2.66)
Yao and Liu, 200328 22/32 15/34 1.56 (1.00–2.43)
Subtotal 41/55 25/54 1.60 (1.15–2.21) 0.86 0.005
After 6 months of treatment Shi et al., 200823 9/11 4/11 2.25 (0.98–5.16)
Yao and Liu, 200328 25/32 17/34 1.56 (1.07–2.29)
Subtotal 34/43 21/45 1.70(1.20 – 2.41) 0.43 0.003
At completion of treatment Yao and Liu, 200328 25/32 16/34 1.66 (1.11–2.48) - 0.01
Intramuscular
injection
Non-RCT After 2 months of treatment Wang et al., 200625 42/63 45/73 1.08 (0.84–1.39)
Li et al., 200824 31/40 22/40 1.41 (1.02–1.95)
Liang, 200327 28/36 19/35 1.43 (1.01–2.03)
Subtotal 101/139 86/148 1.25 (1.05–1.49) 0.31 0.01
After 6 months of treatment Wang et al., 200625 63/63 70/73 1.04 (0.99–1.09) - 0.08
At completion of treatment Wang et al., 200625 63/63 70/73 1.04 (0.99–1.09)
Liang, 200327 33/36 29/35 1.11 (0.92–1.32)
Subtotal 96/99 99/108 1.06 (0.99–1.13) 0.37 0.07
RCT, randomized controlled trial; RR, relative risk; CI, conﬁdence interval.
a p-Value of Chi-square test for heterogeneity.
b p-Value of Z-test for total effect.
c Estimated value.
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conversion rate in the IFN-g-treated group compared with the
control group after 1 month of treatment. Similarly, meta-analysis
of four non-RCTs also showed a statistical effect on the rate after 2,
3, and 6 months of treatment and at the completion of
chemotherapy (Table 3). When we pooled the data of the RCTs
and non-RCTs with aerosolized IFN-g, there was no statistical
heterogeneity among the trials on this outcome after 1, 2, 3, or 6
months of treatment or at the end of treatment. The pooled RR was
1.97 (95% CI 1.20–3.24, p = 0.008) after 1 month of treatment, 1.74
(95% CI 1.30–2.34, p = 0.0002) after 2 months of treatment, 1.53
(95% CI 1.16–2.01, p = 0.003) after 3 months of treatment, 1.57Table 4
Chest radiographic improvement-related results of the trials included in this review
Administration route Trial design Radiographic improvement Trial 
Aerosol RCT At completion of treatment Yang et al., 20
Non-RCT After 2 months of treatment Zhang et al., 2
Xu, 200626
Subtotal 
After 3 months of treatment Yao and Liu, 2
After 6 months of treatment Shi et al., 200
Yao and Liu, 2
Subtotal 
At completion of treatment Yao and Liu, 2
Intramuscular
injection
Non-RCT After 2 months of treatment Li et al., 2008
Wang et al., 2
Liang, 200327
Subtotal 
After 6 months of treatment Wang et al., 2
At completion of treatment Wang et al., 2
Liang, 200327
Subtotal 
RCT, randomized controlled trial; RR, relative risk; CI, conﬁdence interval.
a p-Value of Chi-square test for heterogeneity.
b p-Value of Z-test for total effect.(95% CI 1.20–2.06, p = 0.001) after 6 months of treatment, and 1.55
(95% CI 1.17–2.05, p = 0.002) at the completion of chemotherapy.
When we restricted the analysis to trials in MDR-TB
patients,21,23,28 the pooled RR was 1.57 (95% CI 1.20–2.06,
p = 0.001) after 6 months of treatment and 1.55 (95% CI 1.17–
2.05, p = 0.002) at the end of treatment. As shown by these pooled
RRs with their 95% CIs, combined use of aerosolized IFN-g
improved sputum smear negative conversion at these time-points.
For trials with intramuscular administration of IFN-g, meta-
analysis showed a statistical effect on the sputum smear
conversion after 2 months of treatment (Table 3). The only trial
with subcutaneously administered IFN-g reported no statisticallyTreatment
n/N
Control n/N RR (95% CI) p-Valuea p-Valueb
0921 26/30 21/30 1.24 (0.94–1.63) - 0.13
00922 32/35 21/35 1.52 (1.14–2.03)
13/23 5/20 2.26 (0.98–5.23)
45/58 26/55 1.67 (1.24–2.25) 0.34 0.0006
00328 15/32 8/34 1.99 (0.98–4.05) - 0.06
823 10/11 5/11 2.00 (1.02–3.92)
00328 20/32 16/34 1.33 (0.85–2.08)
30/43 21/45 1.49 (1.03–2.16) 0.32 0.03
00328 25/32 17/34 1.56 (1.07–2.29) - 0.02
24 38/40 36/40 1.06 (0.93–1.20)
00625 63/63 69/73 1.06 (1.00–1.12)
25/36 16/35 1.52 (1.00–2.31)
126/139 121/148 1.10 (0.94–1.28) 0.03 0.23
00625 63/63 72/73 1.01 (0.99–1.04) - 0.32
00625 63/63 72/73 1.01 (0.99–1.04)
33/36 26/35 1.23 (0.99–1.54)
96/99 98/108 1.11 (0.68–1.82) < 0.00001 0.67
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control group in the rate.19
3.3. Chest radiographic improvement
One trial19 reported chest radiographic improvement in the
cavity size of PTB, and eight trials provided the outcome in
improvement rate. Five trials22,24-27 reported chest radiographic
improvement rates after 2 months of treatment, one trial28 after 3
months of treatment, three trials23,25,28 after 6 months of treatment
and four trials21,25,27,28 at the end of treatment.
One RCT19 with aerosolized IFN-g showed no statistically
signiﬁcant differences in the cavity size between the IFN-g-treated
and the control groups after 4 months of treatment (cavity in mm
18  17 vs. 20  16, p = 0.65). Similarly, another RCT reported no
statistically signiﬁcant differences in radiographic improvement rates
between the groups at the completion of chemotherapy. Nonetheless,
meta-analysis of four non-RCTs with aerosolized IFN-g showed
statistical improvement of chest radiograph after 2 and 6 months of
treatment, and at the completion of chemotherapy (Table 4). When
we pooled the data of the randomized and non-randomized trials on
the rate at the completion of chemotherapy, there was no statistical
heterogeneity between the trials and the pooled RR was 1.38 (95% CI
1.10–1.17, p = 0.006).
For trials with intramuscular administration of IFN-g, the three
non-RCTs showed no statistical effect on the rate after 2 or 6
months of treatment or at the completion of treatment (Table 4).
The only RCT19 with subcutaneously administered IFN-g showed
no statistically signiﬁcant differences in the cavity size between
the IFN-g-treated and the control groups after 4 months of
treatment (cavity size in mm 29  24 vs. 20  16, p = 0.10).
3.4. Biochemical variables reﬂecting immune function
One RCT with aerosolized IFN-g reported CD4 T cells counts and
CD4/CD8 ratios, which were higher in the IFN-g-treated group after
3 months of treatment compared with the control group.21The other
RCT with aerosolized or subcutaneously administered IFN-g, instead
of providing concrete data, reported levels of inﬂammatory
cytokines in 24-h bronchoalveolar lavage supernatants with ﬁgures
and found a signiﬁcant decline in the levels of these cytokines from
baseline to 4 months only in the aerosolized IFN-g group.19
Two of three trials with intramuscularly administered IFN-g
measured serum IFN-g and IL-4 levels after 2 months of
treatment,24,25 with no signiﬁcant heterogeneity being detected
in serum IFN-g levels between the trials: the pooled WMD was
0.04 (95% CI 0.01–0.08; p = 0.01). Signiﬁcant heterogeneity
between trials was detected in serum IL-4 levels: the pooled
WMD was –0.03 (95% CI –0.12–0.06; p = 0.53).
3.5. Adverse effects
Four of six trials with aerosolized IFN-g provided data on the
total adverse effects.21–23,26 There was no statistically signiﬁcantTable 5
Adverse effects-related results of the trials with aerosolized interferon-gamma
Trial design Trial Treatment n/N Co
RCT Yang et al., 200921 8/30 7/
Non-RCT Zhang et al., 200922 10/35 15
Shi et al., 200823 7/11 6/
Xu, 200626 2/23 2/
Total 27/99 30
RCT, randomized controlled trial; RR, relative risk; CI, conﬁdence interval.
a p-Value of Chi-square test for heterogeneity.
b p-Value of Z-test for total effect.heterogeneity among trials (I2 = 0%, p = 0.65), and the pooled RR
was 0.89 (95% CI 0.59–1.35, p = 0.59) (Table 5). With respect to
severe adverse effects, one RCT21 with aerosolized IFN-g reported
that only one patient in the IFN-g-treated group stopped treatment
because of a severe photosensitivity reaction caused by sparﬂox-
acin. Another RCT19 with aerosolized or subcutaneously adminis-
tered IFN-g reported that ﬁve patients did not complete the trial
due to serious adverse events, including one patient in the
aerosolized IFN-g group, three patients in the subcutaneously
administered IFN-g group, and one patient in the control group.
Nonetheless, these severe adverse events were not thought to be
related to the IFN-g and/or anti-TB regimens. The other seven trials
all reported no discontinuation of treatment because of severe
adverse effects. No deaths associated with IFN-g and/or anti-TB
regimens were reported in any trial.
3.6. Bacteriological relapse
Data on bacteriological relapse were not available for eight
trials because the trials were not followed-up after completion of
chemotherapy. The remaining trial, an RCT,19 reported no relapse
within 6 months after treatment completion. Besides the above-
mentioned outcome, the RCT reported patient respiratory symp-
toms and found a signiﬁcant reduction in the prevalence of fever,
wheeze, and night sweats in the aerosolized and subcutaneously
administered IFN-g groups compared with the control group after
1 month of treatment.
4. Discussion
This systematic review identiﬁed controlled clinical trials with
adjunctive IFN-g therapy for PTB, and a meta-analysis was
performed according to the route of administration of IFN-g. All
trials included in this study did not have remarkably large sample
sizes, which made it difﬁcult to ﬁnd small- to moderate-sized
effects of IFN-g from a single trial; meta-analysis as used in this
study could make up for this disadvantage to some degree, since
the analysis is a method of obtaining a sufﬁcient sample size to
conclusively detect a small treatment effect by combining trials,
even when no single trial has an adequate sample size. Our meta-
analysis demonstrated that aerosolized IFN-g (three times weekly)
had statistical beneﬁts on sputum negative conversion and chest
radiographic improvement, and that intramuscular administration
of IFN-g had a statistical effect on sputum negative conversion. The
ﬁndings suggest that IFN-g, especially by aerosol, could be
beneﬁcial in PTB.
This is the ﬁrst systematic review of controlled clinical trials
with IFN-g for TB. A recent published study, by reviewing early
experimental studies and uncontrolled studies of IFN-g, estab-
lished that IFN-g plays an essential role in acquired protective
immunity against pathogenic mycobacteria and other intracellular
pathogens.31 Our systematic review of nine available controlled
clinical trials, showed a positive effect of IFN-g on TB from the
clinical point of view, and a more precise estimate of thentrol n/N RR (95% CI) p-Valuea p-Valueb
30 1.14 (0.47–2.75)
/35 0.67 (0.35–1.28)
11 1.17 (0.58–2.35)
20 0.87 (0.13–5.62)
/96 0.89 (0.59–1.35) 0.65 0.59
X.-F. Gao et al. / International Journal of Infectious Diseases 15 (2011) e594–e600 e599magnitude of the effect, and found a statistical effect on chest
radiograph only in patients given aerosolized IFN-g, but not for
intramuscularly or subcutaneously administered IFN-g. Interest-
ingly, in a randomized controlled trial with aerosolized IFN-a – a
type I interferon – given for 2 months as an adjuvant in 20 drug-
sensitive TB patients, Giosue` et al. also found improvements in the
high-resolution computed tomography scores only in the IFN-a-
treated group.32 In contrast with the negative effects of intramus-
cularly administered IFN-g on chest radiograph, a pilot study of 6
months of intramuscular administration of IFN-g as adjuvant at 1
MU per dose to standard chemotherapy in eight MDR-TB patients,
showed sputum conversion within 3 months and marked
improvement of chest radiograph.13 However, this was not a
controlled trial, and the dosage and duration of IFN-g given in the
trial were different from those given in the trials included in our
study. Intramuscular administration of IFN-g was given at 1 MU
per dose three times weekly for 2 months in the included trials. No
trials directly compared the effects of aerosolized and intramus-
cularly administered IFN-g on clinical outcomes. One trial directly
compared aerosolized and subcutaneously administered IFN-g in
PTB patients, ﬁnding that only aerosolized IFN-g, not subcutane-
ously administered IFN-g, was effective in clearing the sputum of
M. tuberculosis and reducing the spontaneous release of inﬂam-
matory cytokines in 24-h bronchoalveolar lavage supernatants.19
It is worth noting that in patients with MDR-TB, the adjunctive
use of aerosolized IFN-g appeared to improve sputum negative
conversion during the whole course of treatment, and chest
radiographs after 2 or 6 months of treatment. These ﬁndings were
similar to the results in one uncontrolled study, which, with
aerosolized IFN-g as adjuvant at 5 MU three times weekly for 1
month in ﬁve pulmonary MDR-TB patients, showed sputum
negative conversion and cavitary lesion reduction in all ﬁve
patients.14 A similar study by Koh et al.,16 with aerosolized IFN-g
as adjuvant at 2 MU three times weekly in six refractory
pulmonary MDR-TB patients for 6 months, reported radiological
improvement in ﬁve patients. Considering that the number of
MDR-TB patients continues to increase worldwide and that only
about 60% of patients are disease-free,33 adjunctive therapy using
IFN-g via aerosol might be a beneﬁcial choice for the early
treatment of MDR-TB.
There are several limitations with regard to the results obtained
in this study. The quality of the trials included in the study was
low; this could lead to bias. The trials were not blinded, for
example, which might have inﬂuenced the original evaluation of
the outcomes. Both randomized and non-randomized trials were
included in the study. Non-RCTs compared with RCTs may tend to
exaggerate treatment effects.34,35 Therefore we separately
reviewed the results of RCTs and non-RCTs; statistical heteroge-
neity, which might result from the difference in the allocation
methods for pooling the data of RCTs and non-RCTs, was not found
in any outcome. Similarly, statistical heterogeneity in the doses of
aerosolized IFN-g was not found either. The optimal dose of IFN-g
via aerosol for TB remains uncertain. In patients with MDR-TB,
aerosol of 5 MU showed advantages in sputum conversion,
radiograph, and body weight.14 In healthy volunteers, IFN-g was
inhaled in single doses of up to 20 MU and multiple doses of 5 MU.
Adverse events were limited to uncommon transient cough
following administration; also, one subject had a transient
decrease in white blood cell count.36–38 In patients with mild to
moderate cystic ﬁbrosis lung disease, higher rates of adverse
events were seen in patients receiving higher doses of aerosolized
IFN-g.39 In our study, the dose range of 1 MU to 5 MU for
aerosolized IFN-g was well tolerated by the TB patients. In
addition, only one trial provided information on relapse, which is
not enough to assess the long-term beneﬁts of IFN-g. Therefore,
additional studies are required to carefully consider the dose, long-term beneﬁts, and length of treatment of aerosolized IFN-g in the
future.
In conclusion, our systematic review suggests that adjunctive
therapy with IFN-g, especially by aerosol, might be useful and
acceptable for the treatment of PTB. Due to the limited number of
RCTs identiﬁed in this study, large RCTs need to be conducted and
the systematic review needs to be renewed in the future to further
evaluate the efﬁcacy and safety of this adjunctive therapy.
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